CJD

HCW Announces Pre-Leasing of Tucson Landing: A Luxury Apartment Development in Tucson, AZ

Retrieved on: 
Thursday, October 19, 2023
MEP, MEB, Interstate 19, Engineering, Irvington Road station, Crossland Construction Company, Interstate Highway System, HCW, Freedom, CJD, Property management, Hotel, PHOENIX

PHOENIX, Oct. 19, 2023 /PRNewswire-PRWeb/ -- HCW is proud and MEB Management Services are thrilled to announce Tucson Landing a 210-unit, gated luxury apartment community in Tucson, AZ is now pre-leasing units with move-in dates starting from December 1st. Located on 8.5 acres along Interstate 19 and Irvington Road, Tucson Landing enjoys a prime location adjacent to the vibrant Tucson Spectrum outdoor mall within the 65-acre mixed-use development, The Landing.

Key Points: 
  • HCW is proud and MEB Management Services are thrilled to announce Tucson Landing a 210-unit, gated luxury apartment community in Tucson, AZ is now pre-leasing units with move-in dates starting from December 1st.
  • PHOENIX, Oct. 19, 2023 /PRNewswire-PRWeb/ -- HCW is proud and MEB Management Services are thrilled to announce Tucson Landing a 210-unit, gated luxury apartment community in Tucson, AZ is now pre-leasing units with move-in dates starting from December 1st.
  • Rick Huffman, HCW's President & CEO, expressed his excitement, stating, "Tucson Landing will set a new standard for luxury rental living in the Tucson community.
  • These exceptional amenities combine to establish Tucson Landing as the foremost luxury apartment community in the area.

José Baselga Research Fund Announces First-Ever Grant to Advance Prion Disease Research

Retrieved on: 
Tuesday, March 21, 2023
Research, Hospitals, Clinical Trials, General Health, University, Pharmaceutical, Health, Science, Education, Other Science, Creutzfeldt–Jakob disease, Harvard Medical School, CJD, Prion, José Baselga, Alexion, Memory, Pharmaceutical industry

The José Baselga Research Fund (JBRF), supported by Alexion, AstraZeneca Rare Disease, today announced the initiation of the Global José Baselga Research Grant (Baselga Grant), an annual $75,000 grant to advance the treatment of prion diseases, a group of rare progressive neurodegenerative disorders.

Key Points: 
  • The José Baselga Research Fund (JBRF), supported by Alexion, AstraZeneca Rare Disease, today announced the initiation of the Global José Baselga Research Grant (Baselga Grant), an annual $75,000 grant to advance the treatment of prion diseases, a group of rare progressive neurodegenerative disorders.
  • JBRF was created by the Baselga family in memory of Dr. José Baselga, a physician-scientist who dedicated his life to the advancement of cancer therapy before passing away two years ago today from Creutzfeldt-Jakob Disease (CJD), an extremely rare, fatal neurodegenerative condition.
  • The Baselga Grant will honor Jose’s legacy and support scientists in the pursuit of understanding, and eradicating, prion diseases such as CJD.
  • The project must have direct applicability and relevance to understanding the pathophysiology or other aspects of prion diseases, developing therapies, or mechanisms for earlier detection of prion disease.

ENEOS UNVEILS AMBITIOUS 2022 SEMA SHOW ACTIVATION

Retrieved on: 
Tuesday, November 1, 2022
Dai, Titan, Frontier, Pit, SEMA, CNC, 3D, World Rally Championship, Electrification, STI, Integra, Efficiency, Rubber industry in Malaysia, Subaru, RWD, Acura, Lucas Oil Off Road Racing Series, DIY, Porsche, ENEOS, Maintenance, CJD, GT3, Subaru Impreza, Nissan, Multimedia, Pikes Peak, Datsun, Nissan Titan, 521, Central Hall, VAD, BorgWarner, Bilstein, Motor vehicle, Vibrant consonant, Eibach

CHICAGO, Nov. 1, 2022 /PRNewswire/ -- ENEOS, Japan's largest oil company and supplier to the majority of Asian vehicle manufacturers, has a major presence at the SEMA Show in Las Vegas, including a booth (# 23819) in Central Hall.

Key Points: 
  • CHICAGO, Nov. 1, 2022 /PRNewswire/ -- ENEOS, Japan's largest oil company and supplier to the majority of Asian vehicle manufacturers, has a major presence at the SEMA Show in Las Vegas, including a booth (# 23819) in Central Hall.
  • Display vehicles showcase many ENEOS products, including its Racing Series motor oils, EV Fluid Line, transmission fluids, and more.
  • Built by Faruk Kugay at DevSpeed Motorsports, ENEOS will display his 2007 Porsche 911 GT3 with Subaru Impreza STI EJ25 engine conversion.
  • Other vehicles presented by ENEOS at SEMA 2022 include the Evasive Motorsports Tesla Model 3 Pikes Peak race car, which was used as a testbed for the new ENEOS EV Fluid Line, designed to help increase efficiency and durability of electric vehicles.

Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

Retrieved on: 
Tuesday, September 13, 2022
Tauopathy, FFI, Risk, Superoxide dismutase, Inflammation, Variant Creutzfeldt–Jakob disease, Memory, Human, FTD, Twitter, NYSE, Brain, AD, Hans Gerhard Creutzfeldt, FSE, BSE, EUE, Neurodegeneration, Parkinson's disease, LinkedIn, Company, GSS, CWD, Cognition, Stroke, Bovine spongiform encephalopathy, CTE, Forward-looking statement, U.S. Securities and Exchange Commission, Prion, Patient, CEO, Creutzfeldt–Jakob disease, Huntington's disease, Chronic traumatic encephalopathy, Annual report, TDP43, Scrapie, Toxicity, ALS, Security (finance), Pharmacokinetics, Chronic wasting disease, Frontotemporal dementia, PD, Gian Maria Annovi, TME, Patent, Axonal transport, Alzheimer's disease, CJD, Pharmaceutical industry, Vaccine, Huntingtin

The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap.

Key Points: 
  • The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap.
  • A method of treating amyloid lateral sclerosis, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of superoxide dismutase protein1 and TDP43.
  • A method of treating Huntington's disease, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of Huntingtin protein.
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .

20 Grand Kicks Off Highly Anticipated Leasing Efforts

Retrieved on: 
Monday, July 25, 2022
Pleasure, Interior, George Washington Bridge Plaza, Research, Partnership, Collection, Marketing, George Washington Bridge, Multimedia, CJD, Philosophy, Grand Avenue, Individual, Heart, Architecture, Rest, Restaurant, Tourism, Interior design, Grand

ENGLEWOOD, N.J., July 25, 2022 /PRNewswire/ -- 20 Grand kicked off highly anticipated leasing efforts this week.

Key Points: 
  • ENGLEWOOD, N.J., July 25, 2022 /PRNewswire/ -- 20 Grand kicked off highly anticipated leasing efforts this week.
  • Featuring high-end, hotel-inspired amenities, the 5-story 20 Grand anticipates opening its doors to residents in late August 2022.
  • CJ Dalton's broker, Taryn Byron, will be handling all leasing and marketing efforts for 20 Grand.
  • 20 Grand is located at 20 Grand Avenue in Englewood.

Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals

Retrieved on: 
Thursday, November 4, 2021
Safety, Anemia, Plasticizer, History, EUR, Commercial Operating System (COS), MCE, Multimedia, Health, GRF, ADR, Allergy, PVC, Coagulation, Blood, Transfusion medicine, Ovarian hyperstimulation syndrome, Creutzfeldt–Jakob disease, Hematology, Food, Water, Regulation of tobacco by the U.S. Food and Drug Administration, Respiratory distress syndrome, S.A, Solution, Plasmapheresis, Pharmacy, Hospital, Excipient, Red blood cell, Carbon, Dehydration, Hypersensitivity, CJD, Hypovolemia, Phthalate, Sale, Legislation, Heart failure, Patient, Heart, Plasma, Hemolysis, Anaphylaxis, Pulmonary edema, Paracentesis, Hypervolemia, NASDAQ, FDA, Electrolyte, Adult, Polyvinyl chloride, DEHP, Blood product, Medical device, Birth control

"This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."

Key Points: 
  • "This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."
  • Sustainability was key for Grifols when developing the environmentally friendly ALBUTEIN FlexBag.
  • Both the ALBUTEIN FlexBag flexible container and protective overwrap are latex-free and do not contain polyvinyl chloride (PVC), diethylhexyl phthalate (DEHP) or other plasticizers.
  • The launch of ALBUTEIN FlexBag solidifies Grifols commitment to R+D+i, which has enabled the company to further expand its industry-leading portfolio of plasma-derived medicines for patients and healthcare professionals.

Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1

Retrieved on: 
Wednesday, October 20, 2021
Virus, Mouth, Security (finance), Ligneous conjunctivitis, Human, Fatigue, Patient, Bleeding, Hypersensitivity, Immune system, Risk, Anticoagulant, Visual impairment, Private Securities Litigation Reform Act, Xerostomia, Collection, Gamma globulin, Headache, Macrocytic anemia, Fibrin, Abdominal pain, Acquisition, Anti-tetanus immunoglobulin, Nausea, U.S. Securities and Exchange Commission, VTE, Dizziness, FDA, Constipation, Hans Gerhard Creutzfeldt, Forward-looking statement, Plasma, Arthralgia, Pathogen, Back pain, Castelvecchio Pascoli, Anaphylaxis, Shortness of breath, Sumathi Best Television Current Reporting Award, CJD, Bloating, Degenerative disease, Goal, Thrombosis, Fetus, Research, Creutzfeldt–Jakob disease, Infection, Paroxysmal extreme pain disorder, Plasmin, Pharmaceutical industry, Medical device, Vaccine

"The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.

Key Points: 
  • "The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.
  • RYPLAZIM meets an urgent unmet medical need for people who face plasminogen deficiency type 1, a potentially devastating, but treatable, medical condition.
  • The Prometic deal also brings more cutting-edge purification technology to the Kedrion Biopharma group.
  • Kedrion Biopharma is ramping up RYPLAZIM production capacity to meet patient demand and anticipates RYPLAZIM will be available in limited quantities in 2022.

One Park Condos Finalist for HGTV's Designer of the Year Award

Retrieved on: 
Wednesday, September 1, 2021
The Living Room, DMG, Investment, Television, Social media, Research, CJD, Cliffside Park, New Jersey, Lamborghini, Travel, Marketing, HGTV, Car, Twenty-five Year Award, Ferrari, Interior, Marriage, Living room, Housing, Culture, One Park West, Wall Street, Bath, Hotel

CLIFFSIDE PARK, N.J., Sept. 1, 2021 /PRNewswire-PRWeb/ -- Luxury condo tower One Park Condos on New Jersey's gold coast has been named a finalist in HGTV's upcoming Designer of the Year Award.

Key Points: 
  • CLIFFSIDE PARK, N.J., Sept. 1, 2021 /PRNewswire-PRWeb/ -- Luxury condo tower One Park Condos on New Jersey's gold coast has been named a finalist in HGTV's upcoming Designer of the Year Award.
  • "I wanted to showcase art, so we worked with Dru on selecting a piece for the master bedroom.
  • "When we were conceptualizing the unit, I expressed to Joe the ideal client for One Park and what their lifestyle is like."
  • "One Park attracts a very fashion forward resident, who enjoys travel, art, and culture with a comfortable, laid back style.

U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine

Retrieved on: 
Saturday, August 14, 2021
Biotechnology, FDA, Infectious Diseases, Health, Pharmaceutical, Blood, European Centre for Disease Prevention and Control, Clinical trial, Water, Research, Muscle weakness, Control, Degenerative disease, Inc., Elsevier, Safety, Vaccine, PFE, Human, CJD, LinkedIn, Allergy, Risk, FDA, Vaccination, Tick-borne encephalitis, Facebook, News, Hans Gerhard Creutzfeldt, Regulation of tobacco by the U.S. Food and Drug Administration, Adult, Fever, NYSE, Creutzfeldt–Jakob disease, Science, COVID-19, U.S. Securities and Exchange Commission, Fatigue, Tick, Profile, Anaphylaxis, CDC, TBE, Restless, Doctor of Philosophy, ACIP, YouTube, Brain, Twitter, Review, ECDC, Health, Headache, R, IJMM, Pharmaceutical industry, Animal

This vaccine has helped to protect millions of people in TBE endemic regions since its first approval outside the U.S. 45 years ago.

Key Points: 
  • This vaccine has helped to protect millions of people in TBE endemic regions since its first approval outside the U.S. 45 years ago.
  • A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans.
  • Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies.
  • Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity.